CRISPR Therapeutics, Vertex Report First Data from Trials of Gene-Editing Treatment CTX001

GEN | November 19, 2019

CRISPR Therapeutics and Vertex Pharmaceuticals today reported preliminary, mostly-positive safety and efficacy data from the first two patients enrolled in two Phase I/II trials assessing their CRISPR/Cas9 gene-edited therapy CTX001 for a pair of blood disorders—the first clinical trial of a gene-editing candidate sponsored by U.S. companies. “We are very encouraged by these preliminary data, the first such data to be reported for patients with beta thalassemia and sickle cell disease treated with our CRISPR/Cas9 edited autologous hematopoietic stem cell candidate CTX001,” CRISPR Therapeutics CEO Samarth Kulkarni, PhD, said in a statement. “These data support our belief in the potential of our therapies to have meaningful benefit for patients following a one-time intervention. We continue to enroll these studies as we drive forward to develop CRISPR/Cas9 therapies as a new class of transformative medicines to treat serious diseases.” Added Vertex Chairman, President and CEO Jeffrey Leiden, MD, PhD: “The data we announced today are remarkable and demonstrate that CTX001 has the potential to be a curative CRISPR/Cas9-based gene-editing therapy.”

Spotlight

Watch this simple yet engaging video on the basics of drugs, drug targets and molecular interaction. It is illustrative and informative, and you will definitely enjoy watching it. To learn more about drugs and drug targets, Bentham Science Publishers offer a number of journals, such as Current Drug Targets, Current Drug Therapy, Current Drug Metabolism, Current Drug Safety etc.

Spotlight

Watch this simple yet engaging video on the basics of drugs, drug targets and molecular interaction. It is illustrative and informative, and you will definitely enjoy watching it. To learn more about drugs and drug targets, Bentham Science Publishers offer a number of journals, such as Current Drug Targets, Current Drug Therapy, Current Drug Metabolism, Current Drug Safety etc.

Related News

BioLineRx Announces Positive Results from a Planned Interim Analysis of the Ongoing GENESIS Phase 3 Trial of Motixafortide for Stem Cell Mobilization

BioLineRx | October 30, 2020

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a planned interim analysis of the ongoing GENESIS Phase 3 trial of motixafortide for stem cell mobilization (SCM) in multiple myeloma patients. At a meeting of the study's independent Data Monitoring Committee (DMC), a planned interim analysis of the study's primary endpoint was conducted independently by the DMC. Based on the statistically significant evidence favoring treatment with motixafortide, the DMC issued a recommendation to the Company that patient enrollment may be ceased immediately, without the need to recruit all 177 patients originally planned for the study. In accordance with the DMC's recommendation, study enrollment is now complete at 122 patients. Full results for the study, including secondary and exploratory efficacy endpoints, as well as extended safety data, will be announced after the last patient enrolled reaches 100 days of follow-up post-transplantation, which is expected to occur in the first half of 2021.

Read More

CELL AND GENE THERAPY

AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for the Research and Development of CAR-T Cell Therapeutics

AbbVie | February 11, 2021

AbbVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome altering biotechnology organization, reported today that they have gone into a cooperation and permit arrangement for the innovative work of fanciful antigen receptor (CAR)- T cell therapeutics. Albeit allogeneic, "off-the-shelf" CAR-T cell therapies have indicated early guarantee in some malignancy patients, the requirement for beating the dismissal of allogeneic CAR-T cells by the host immune system stays a vital test to their more extensive turn of events. Utilizing Caribou's CRISPR genome editing platform to engineer CAR-T cells to withstand have resistant assault would empower the advancement of the next-generation of "off-the-shelf" cellular therapies to benefit a broader patient population. "We are excited to partner with AbbVie on the development of new CAR-T cell therapies. This collaboration validates Caribou's differentiated next-generation CRISPR genome editing technologies that provide best-in-class efficiency and specificity," said Rachel Haurwitz, Ph.D., President and Chief Executive Officer of Caribou. "We believe AbbVie is an ideal partner for Caribou as we expand upon the number of targets and diseases addressable by our technologies. Genome-edited CAR-T cell therapies hold tremendous potential for patients, and this partnership accelerates our ability to address significant unmet medical need." About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. About Caribou Biosciences, Inc. Caribou is a leading clinical-stage CRISPR genome editing biotechnology company founded by pioneers of CRISPR biology. Outside of this collaboration, Caribou is advancing an internal pipeline of allogeneic cell therapies for oncology. CB-010, Caribou's lead allogeneic CAR-T cell program, targets CD19 and is being evaluated in a Phase 1 clinical trial for patients with relapsed/refractory B cell non-Hodgkin lymphoma. CB-011, Caribou's second allogeneic CAR-T cell therapy, targets BCMA for multiple myeloma, and CB-012, Caribou's third allogeneic CAR-T cell therapy, targets CD371 for acute myeloid leukemia. CB-011 and CB-012 are in preclinical development. Additionally, Caribou is developing iPSC-derived allogeneic natural killer (NK) cell therapies for solid tumors. Through its next-generation CRISPR genome editing technologies, Caribou is implementing multiple strategies to boost CAR-T and NK cell persistence to overcome cell exhaustion and to prevent rapid immune-mediated clearance. These sophisticated edits drive the durability of clinical benefit of these off-the-shelf medicines.

Read More

MEDICAL

Suono Bio, Inc. Announces Formulation-Agnostic Platform for the Delivery of RNA Therapeutics

Suono Bio | January 06, 2022

Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract. This latest publication adds to the validation of Suono Bio’s therapeutic delivery platform leveraging low-frequency ultrasound for formulation-agnostic delivery. This technology was originally developed in the laboratory of Institute Professor Robert Langer at MIT to facilitate rapid, local administration of therapeutics to treat serious diseases. “Therapeutic translation of oligos has been hampered by delivery and bioavailability issues with a complicated landscape for chemical-based formulations. This further demonstrates our capability to deliver RNAs and siRNAs to knockdown relevant gene targets without the need for any formulation.” Dr. Carl Schoellhammer, corresponding author, and Suono Bio co-founder In addition to previously demonstrating the preclinical use of siRNAs for treating inflammatory conditions, this latest publication demonstrates the ability to knockdown endogenous genes, including Ctnnb1, the gene encoding for beta-catenin, which plays a role in tumorigenesis in colorectal cancers, for example. ABOUT SUONO BIO Suono Bio was founded by Robert Langer and Giovanni Traverso, a gastroenterologist and biomedical engineer from the Department of Mechanical Engineering, MIT and Brigham and Women’s Hospital, Harvard Medical School, and Dr. Carl Schoellhammer. The company is developing therapeutic products for inflammatory-mediated diseases leveraging their ultra-rapid and formulation independent delivery technology. Suono Bio’s platform enables rapid, localized delivery of small molecules, biologics, and nucleic acids and gene therapies without the need for encapsulation of the therapeutic.

Read More